When Starbucks announced it would stop covering GLP-1 medications for weight loss, benefits leaders recognized the pressure behind that decision. Drugs like Wegovy and Zepbound can cost up to $450 per month post-rebate, and demand keeps climbing. For a large employer, that math turns painful fast.
Cutting coverage can feel like the right response, but it isn’t the only path available to employers. There’s another side to this story, where employers don’t have to choose between protecting their people and protecting their budget.
Why Employers are Stepping Back
The market reality is that most employer plans don’t cover GLP-1s for weight loss. In fact, 80% of employer plans tracked by RxBenefits did not cover GLP-1s last year.
The reasons for this are easy to understand:
- Cost: Due to the high monthly cost of GLP-1s, employers are finding budgets hard to forecast across their workforce. Newer pill versions can cost less but may be less effective.
- Low adherence: According to a recent study, more than 40% of patients stopped taking GLP-1s within a year and close to 60% had stopped by the end of two years.
- Rebound risk: When members stop taking these drugs without clinical support or lifestyle change, they often regain the weight they lost and face other health consequences.
That creates a difficult dynamic. Employers may pay premium prices for treatment that many members do not stay on long term, while the people most likely to benefit risk getting lost in the process.
Dropping coverage may reduce pharmacy spend, but it can also send an unintended message to employees. People managing obesity as a chronic condition may lose access to a treatment their clinicians recommend. That can affect morale — and in a competitive talent market, it may also create challenges for recruiting and retention.
So employers are often left balancing two legitimate priorities: cost control and employee support. But that tradeoff may not be as fixed as it seems.
A Third Option: Structured, Non-PBM Programs
There’s a middle path between covering everything through the pharmacy benefits manager (PBM) and covering nothing at all.
Programs like Tria Health Weight Management and GoodRx Employer Direct, both available through RxBenefits, offer an alternative model outside of the PBM. By using direct-to-employer (DTE) pricing arrangements, they can significantly reduce what employers and/or employees pay for GLP-1 medications. In addition to the drug cost, these programs may also include a per-participant, per-month fee.
Even so, they can still offer a more structured and potentially more affordable option than traditional PBM coverage. The employer can choose to pay for some or all of the drug cost; if they choose not to contribute, the member may still be able to access the medication at a lower cost.
Instead of potentially paying high point of sale costs, employers can get flat, predictable pricing such as:
- Wegovy at $399, regardless of dose or strength
- Zepbound at $399 for 2.5mg/5mg/7.5mg and $415 for 10mg/12.5mg/15mg
That consistency matters. As a member’s dose changes over time, the price stays the same. Employers know what to budget, and members know what to expect. In side-by-side cost comparisons, that can create a meaningful difference.
For RxBenefits customers, the two programs support different priorities. GoodRx Employer Direct is the pricing-focused option, designed to lower cost with a lighter operational lift. Tria Health Weight Management takes a more clinical-first approach, with additional support intended to improve long-term outcomes and savings.
Why Clinical Oversight Changes the Math
Lower pricing solves half the problem. Lasting outcomes solve the other half – and that’s where clinical support earns its place.
Tria Health Weight Management takes a clinical-first approach. Members do not simply receive the medication; they participate in a program that can include:
- Health coaching to build sustainable habits
- Pharmacist check-ins twice a year to monitor progress and safety
- Meal planning to support real lifestyle change
That support can matter. Members who are more engaged may be better positioned to build healthier routines, stay aligned to treatment, and better understand what happens if they discontinue therapy. Over time, that can help employers avoid paying high prices for short-term or poorly supported use.
DTE programs can expand access at a fraction of traditional point-of-sale costs. The difference comes down to how much clinical support an employer wants to build into the model.
The Savings are Real
Does structured management actually move the needle? For employers, the savings show up in two places: predictable drug pricing and better long-term use.
Flat, transparent pricing removes the guesswork from budgeting. Employers can forecast spend with confidence instead of bracing for point-of-sale swings.
Pair that pricing with clinical support, and the risk of paying premium prices for medications members abandon within months is reduced. Those are real dollars preserved in employer plans, without shutting members out of appropriate care.
A Smarter Path Than Dropping Coverage
The real debate is not coverage versus no coverage. It is how to provide access in a way that works for both the plan and the people it serves.
If you’re considering a change to your clients’ GLP-1 strategy, it is worth taking a closer look before walking away entirely. A structured program may help control costs while still keeping members supported.
Ask for a plan-specific analysis and see the side-by-side numbers for yourself. You may find there’s a smarter path than dropping coverage altogether
Learn more:
PBM Contract Terms Decoded: A Plain-Language Glossary for Benefits Advisors, Aug. 26, 2026
4 Reasons the Biosimilar Boom Could Save Your Clients $232 Billion, Aug. 18, 2026
10 Most Expensive Drugs in the U.S.: 2026 Edition, July 21, 2026
